Skip to content

Advertisement

BMC Neurology

Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Previous Page Page 4 of 11 Next Page
  1. Content type: Research article

    To examine whether past and current reserve-related activities make the brain less susceptible to MS pathology (i.e., lesions or disease-related atrophy).

    Authors: Carolyn E. Schwartz, Michael G. Dwyer, Ralph Benedict, Bianca Weinstock-Guttman, Niels P. Bergsland, Jei Li, Murali Ramanathan and Robert Zivadinov

    Citation: BMC Neurology 2016 16:108

    Published on:

  2. Content type: Research article

    This retrospective analysis explored prognostic factors associated with a benign multiple sclerosis (BMS) disease course at baseline and over the 4-year follow-up.

    Authors: Robert Zivadinov, Diane L. Cookfair, Lauren Krupp, Aaron E. Miller, Neil Lava, Patricia K. Coyle, Andrew D. Goodman, Burk Jubelt, Michael Lenihan, Joseph Herbert, Malcolm Gottesman, David H. Snyder, Brian R. Apatoff, Barbara E. Teter, Allan B. Perel, Frederick Munschauer…

    Citation: BMC Neurology 2016 16:102

    Published on:

  3. Content type: Research article

    Patients suffering from several neurologic disorders may bear the “stigma” of their disease, being disqualified from full social acceptance. Although stigma is considered to be present in Multiple Sclerosis (M...

    Authors: Maria Anagnostouli, Serafeim Katsavos, Artemios Artemiadis, Markos Zacharis, Paraskevi Argyrou, Ilia Theotoka, Fotini Christidi, Ioannis Zalonis and Ioannis Liappas

    Citation: BMC Neurology 2016 16:101

    Published on:

  4. Content type: Study protocol

    Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activity with long-term stabilization. However, the benefits of the drug are countered by a risk of developing progressive mul...

    Authors: Tjalf Ziemssen, Achim Gass, Jens Wuerfel, Antonios Bayas, Björn Tackenberg, Volker Limmroth, Ralf Linker, Mathias Mäurer, Judith Haas, Martin Stangel, Matthias Meergans, Olof Harlin and Hans-Peter Hartung

    Citation: BMC Neurology 2016 16:98

    Published on:

  5. Content type: Research article

    In neuromyelitis optica (NMO), one of the underlying pathogenic mechanisms is the formation of antigen-antibody complexes which can trigger an inflammatory response by inducing the infiltration of neutrophils ...

    Authors: Tao Yang, Su Wang, Qi Zheng, Lei Wang, Qian Li, Mingyan Wei, Zongpan Du and Yongping Fan

    Citation: BMC Neurology 2016 16:96

    Published on:

  6. Content type: Research article

    Functional biomarkers able to identify multiple sclerosis (MS) patients at high risk of fast disability progression are lacking. The aim of this study was to evaluate the ability of multimodal (upper and lower...

    Authors: Xavier Giffroy, Nathalie Maes, Adelin Albert, Pierre Maquet, Jean-Michel Crielaard and Dominique Dive

    Citation: BMC Neurology 2016 16:83

    Published on:

  7. Content type: Study protocol

    In people with multiple sclerosis (MS) disabilities and limitations may negatively affect self-efficacy. Lowered self-efficacy has been associated with decreases in health-related quality of life, physical act...

    Authors: Peter Joseph Jongen, Marco Heerings, Rob Ruimschotel, Astrid Hussaarts, Silvia Evers, Lotte Duyverman, Joyce Valkenburg-Vissers, Job Cornelissen, Michel Bos, Maarten van Droffelaar, Wim A. Lemmens, Rogier Donders, Anneke van der Zande and Leo H. Visser

    Citation: BMC Neurology 2016 16:81

    Published on:

  8. Content type: Research article

    The present study was carried out to evaluate cerebral perfusion in multiple sclerosis (MS) patients with a moderate to severe stage of disease. Some patients underwent hyperbaric oxygen therapy (HBOT) and bra...

    Authors: Mina Taghizadeh Asl, Reza Nemati, Negar Chabi, Hooman Salimipour, Iraj Nabipour and Majid Assadi

    Citation: BMC Neurology 2016 16:79

    Published on:

  9. Content type: Research article

    Andrographis paniculata (A. paniculata), a medicinal plant, has shown anti-inflammatory, neuroprotective and antifibrotic effects in animal models as well as clinical efficacy in different studies, including an a...

    Authors: J. C. Bertoglio, M. Baumgartner, R. Palma, E. Ciampi, C. Carcamo, D. D. Cáceres, G. Acosta-Jamett, J. L. Hancke and R. A. Burgos

    Citation: BMC Neurology 2016 16:77

    Published on:

  10. Content type: Debate

    Accumulating evidences from experimental, epidemiologic and clinical studies support the potential linkage between poor vitamin D status and the risk of developing Multiple Sclerosis (MS), as well as, an adver...

    Authors: Soodeh Razeghi Jahromi, Mohammad Ali Sahraian, Mansoureh Togha, Behnaz Sedighi, Vahid Shayegannejad, Alireza Nickseresht, Shahriar Nafissi, Niayesh Mohebbi, Nastran Majdinasab, Mohsen Foroughipour, Masoud Etemadifar, Nahid Beladi Moghadam, Hormoz Ayramlou, Fereshteh Ashtari and Shekoofe Alaie

    Citation: BMC Neurology 2016 16:76

    Published on:

  11. Content type: Study protocol

    Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive neurological condition. It is the most common cause of neurological disability in young adults. Within 15 years of diagnosis, ap...

    Authors: J. A. Freeman, W. Hendrie, S. Creanor, L. Jarrett, A. Barton, C. Green, J. Marsden, E. Rogers and J. Zajicek

    Citation: BMC Neurology 2016 16:62

    Published on:

  12. Content type: Study protocol

    The management of multiple sclerosis (MS) is rapidly changing by the introduction of new and more effective disease-modifying agents. The importance of risk stratification was confirmed by results on disease p...

    Authors: Gustavo Saposnik, Angel Perez Sempere, Roula Raptis, Daniel Prefasi, Daniel Selchen and Jorge Maurino

    Citation: BMC Neurology 2016 16:58

    Published on:

  13. Content type: Research article

    Reversible splenial lesion syndrome (RESLES) is a disorder radiologically characterized by reversible lesion in the splenium of the corpus callosum (SCC). Most of patients with RESLES associated with encephali...

    Authors: Yuanzhao Zhu, Junjun Zheng, Ling Zhang, Zhenguo Zeng, Min Zhu, Xiaobin Li, Xiaoliang Lou, Hui Wan and Daojun Hong

    Citation: BMC Neurology 2016 16:49

    Published on:

  14. Content type: Review

    Leakage of the blood–brain barrier (BBB) is a common pathological feature in multiple sclerosis (MS). Following a breach of the BBB, albumin, the most abundant protein in plasma, gains access to CNS tissue whe...

    Authors: Steven M. LeVine

    Citation: BMC Neurology 2016 16:47

    Published on:

  15. Content type: Study protocol

    Alemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In previous phase II and III clinical trials, alemtuzumab has proven superior efficacy to subcut...

    Authors: Tobias Ruck, Ali Maisam Afzali, Karl-Friedrich Lukat, Maria Eveslage, Catharina C. Gross, Steffen Pfeuffer, Stefan Bittner, Luisa Klotz, Nico Melzer, Heinz Wiendl and Sven G. Meuth

    Citation: BMC Neurology 2016 16:34

    Published on:

  16. Content type: Research article

    There is limited knowledge regarding how depressive symptoms and a cluster of specific mood symptoms in people with multiple sclerosis (MS) vary over time and how they are influenced by contributing factors. T...

    Authors: Sverker Johansson, Kristina Gottberg, Marie Kierkegaard and Charlotte Ytterberg

    Citation: BMC Neurology 2016 16:32

    Published on:

  17. Content type: Research article

    People with multiple sclerosis (MS) are increasingly using the Internet in the daily management of their condition. They search for high-quality information in plain language, from independent sources, based o...

    Authors: Cinzia Colombo, Graziella Filippini, Anneliese Synnot, Sophie Hill, Roberta Guglielmino, Silvia Traversa, Paolo Confalonieri, Paola Mosconi and Irene Tramacere

    Citation: BMC Neurology 2016 16:30

    Published on:

Previous Page Page 4 of 11 Next Page

2016 Journal Metrics

Advertisement